Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease.
Sungho BeaHwa Yeon KoJae Hyun BaeYoung Min ChoYoosoo ChangSeungho RyuChristopher D ByrneJu Young ShinPublished in: Gut (2024)
In this nationwide cohort study, SGLT-2i was associated with a lower risk of hepatic decompensation events in patients with MASLD compared with TZD, while demonstrating similar effectiveness to GLP-1RA.